When tumors were stratified into high and low EGFR expression groups ( IHC score threshold @ ; scale @-@ ) , a stronger antitumor activity was seen in the high EGFR expression group compared with the low EGFR expression group in both the cetuximab monotherapy and cisplatin plus cetuximab combination therapy settings .